At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
09637 ALEBUND-B
Market Closed 11-06 16:08:50
19.180
+0.710
+3.84%
High19.550Low17.980Vol667.42K
Open18.000D1 Closing18.470Amplitude8.50%
Mkt Cap6.67BTradable Cap4.53BTotal Shares348.00M
T/O12.56MT/O Rate0.28%Tradable Shares236.00M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Alebund Pharmaceuticals Completes Additional Share Buyback; Treasury Stock Rises to 151,400 H Shares
Bulletin Express  ·  11-06 22:20
Alebund Pharmaceuticals Completes Additional Share Buyback; Treasury Stock Rises to 151,400 H Shares
Alebund Pharmaceuticals Files Next-Day Disclosure with HKEX Announcing Share Buyback
Reuters  ·  11-06 22:03
Alebund Pharmaceuticals Files Next-Day Disclosure with HKEX Announcing Share Buyback
Alebund Pharma Buys Back 6,600 H-Shares; Outstanding Float Marginally Trimmed
Bulletin Express  ·  11-05 22:20
Alebund Pharma Buys Back 6,600 H-Shares; Outstanding Float Marginally Trimmed
ALEBUND-B (09637) Spends About HK$115,400 to Buy Back 6,600 Shares on November 5
Stock News  ·  11-05 22:06
ALEBUND-B (09637) Spends About HK$115,400 to Buy Back 6,600 Shares on November 5
Alebund Pharmaceuticals Files Next-Day Disclosure Return with HKEX Announcing Share Buyback
Reuters  ·  11-04 22:08
Alebund Pharmaceuticals Files Next-Day Disclosure Return with HKEX Announcing Share Buyback
Alebund-B Reports No Share Capital Changes in October; Public Float Meets 19.53% Requirement
Bulletin Express  ·  11-04
Alebund-B Reports No Share Capital Changes in October; Public Float Meets 19.53% Requirement
AleBund-B (09637) Fires First Shot in HK$100 Million Buyback Plan with Nearly HK$1 Million Repurchase
Stock News  ·  11-03
AleBund-B (09637) Fires First Shot in HK$100 Million Buyback Plan with Nearly HK$1 Million Repurchase
Alebund Pharma Repurchases 58,300 H-Shares for HKD 1.00 Million, Reducing Free Float by 0.02%
Bulletin Express  ·  11-02
Alebund Pharma Repurchases 58,300 H-Shares for HKD 1.00 Million, Reducing Free Float by 0.02%
Alebund Pharmaceuticals Files Next-Day Disclosure with HKEX on Share Repurchase
Reuters  ·  11-02
Alebund Pharmaceuticals Files Next-Day Disclosure with HKEX on Share Repurchase
Hong Kong Stock Movement: Alebund-B (09637) Surges Over 10% in Early Trading as Partner R1 Presents AP306 Global Phase IIb Multi-Regional Clinical Trial Design Poster at ASN Kidney Week
Stock News  ·  10-27
Hong Kong Stock Movement: Alebund-B (09637) Surges Over 10% in Early Trading as Partner R1 Presents AP306 Global Phase IIb Multi-Regional Clinical Trial Design Poster at ASN Kidney Week
Alebund Partner R1 Presents Phase IIb Trial Design for AP306 in Hyperphosphatemia
Reuters  ·  10-23
Alebund Partner R1 Presents Phase IIb Trial Design for AP306 in Hyperphosphatemia
Alebund Pharmaceuticals Announces Poster Presentation by Partner R1 Therapeutics of Global Phase Iib Multi-Regional Clinical Trial Design for AP306 at Asn Kidney Week 2026
THOMSON REUTERS  ·  10-23
Alebund Pharmaceuticals Announces Poster Presentation by Partner R1 Therapeutics of Global Phase Iib Multi-Regional Clinical Trial Design for AP306 at Asn Kidney Week 2026
ALEBUND-B (09637) Plans H Share Buyback of Up to HK$100 Million
Stock News  ·  10-20
ALEBUND-B (09637) Plans H Share Buyback of Up to HK$100 Million
Alebund Pharmaceuticals (Jiangsu) - Board Resolves to Repurchase H Shares up to Hk$100 Mln
THOMSON REUTERS  ·  10-20
Alebund Pharmaceuticals (Jiangsu) - Board Resolves to Repurchase H Shares up to Hk$100 Mln
Alebund Pharmaceuticals (Jiangsu) Ltd - On-Market Share Repurchase
THOMSON REUTERS  ·  10-20
Alebund Pharmaceuticals (Jiangsu) Ltd - On-Market Share Repurchase
ALEBUND-B Shares Surge Over 47% in Early Trading as AP308 Gains FDA Clinical Clearance and Domestic Acceptance
Deep News  ·  10-20
ALEBUND-B Shares Surge Over 47% in Early Trading as AP308 Gains FDA Clinical Clearance and Domestic Acceptance
AleBund-B Shares Jump Nearly 7% in Early Trading as Institution Says AP308 Could Unlock a Broader IgA Nephropathy Market
Stock News  ·  10-07
AleBund-B Shares Jump Nearly 7% in Early Trading as Institution Says AP308 Could Unlock a Broader IgA Nephropathy Market
Five Straight Gains, Outperforming Hang Seng by 18.5 Points Since the Recent Low: Is the Kidney Disease Wave Finally Here?
Stock News  ·  10-06
Five Straight Gains, Outperforming Hang Seng by 18.5 Points Since the Recent Low: Is the Kidney Disease Wave Finally Here?
Alebund Pharmaceuticals Reports Stable Share Capital and Maintains Public Float Compliance for September 2026
Bulletin Express  ·  10-06
Alebund Pharmaceuticals Reports Stable Share Capital and Maintains Public Float Compliance for September 2026
Alebund Posts 1H26 Revenue Surge on Licensing Deal; AP301 China NDA Accepted
Bulletin Express  ·  09-17
Alebund Posts 1H26 Revenue Surge on Licensing Deal; AP301 China NDA Accepted

Introduction

Company Name.
ALEBUND-B
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
Alebund Pharmaceuticals (Jiangsu) Ltd is a China-based company principally engaged in biopharmaceutical business. The Company’s product portfolio in clinical and preclinical stages consists of one core product AP301 and other product candidates, including one late-clinical-stage product candidate AP306, one early-clinical-stage product candidate (AP303), and four preclinical product candidates (AP308, AP304, AP305, and AP307). The Company mainly operates its businesses in the domestic market and overseas markets.
Issue price:
--